Evolent Health (EVH) Reports Q4 Loss, Lags Revenue Estimates
Evolent Health (EVH) came out with a quarterly loss of $0.02 per share in line with the Zacks Consensus Estimate. This compares to earnings of $0.23 per share a year ago.
Evolent Health (EVH) Q4 Earnings on the Horizon: Analysts' Insights on Key Performance Measures
Beyond analysts' top -and-bottom-line estimates for Evolent Health (EVH), evaluate projections for some of its key metrics to gain a better insight into how the business might have performed for the quarter ended December 2024.
Earnings Preview: Evolent Health (EVH) Q4 Earnings Expected to Decline
Evolent Health (EVH) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Evolent dips after Truist warns guidance may be 'significantly' below consensus
Truist analyst Jailendra Singh caught up with Evolent Health post its presentation at an investor healthcare conference and also noted that the company released an 8-K earlier in the week outlining some preliminary views on 2025. Evolent is encouraging investors to use Q4 EBITDA run-rate as the baseline for 2025 and the firm now sees the company's 2025 guidance range coming in "significantly below consensus," the analyst tells investors. Using about $25M of Q4 EBITDA as a baseline, the firm infers that Evolent is suggesting a potential initial FY25 EBITDA range of $140M-$170M, said the analyst, who has a Buy rating and $20 price target on the shares. In Wednesday trading, Evolent shares slid 10% to $10.02.
Evolent Health: A Shot At Revival After Market Bruising
Evolent Health has seen a significant 50% drop due to a Q3 earnings miss and high medical costs. Despite setbacks, Evolent secured record-breaking new business deals and anticipates over 15% annual revenue growth, driven by rate increases and strategic partnerships. EVH stock appears undervalued with a P/E ratio of 16.57, suggesting a potential contrarian buy opportunity given its long-term growth prospects.
Evolent Health, Inc. (EVH) Q3 2024 Earnings Call Transcript
Evolent Health, Inc. (NYSE:EVH ) Q3 2024 Earnings Conference Call November 7, 2024 5:00 PM ET Participants Seth Blackley - Chief Executive Officer John Johnson - Chief Financial Officer Seth Frank - Vice President, Investor Relations Conference Call Participants Charles Rhyee - TD Cowen Jailendra Singh - Truist Securities Jeff Garro - Stephens Stephanie Davis - Barclays Ryan Daniels - William Blair Matthew Gillmor - KeyBanc Kyle Aikman - J.P. Morgan Richard Close - Canaccord Genuity Sean Dodge - RBC Capital Markets Jessica Tassan - Piper Sandler Kevin Caliendo - UBS Daniel Grosslight - Citi David Larsen - BTIG Operator Welcome to the Evolent Earnings Conference Call for the Third Quarter Ended September 30, 2024.
Compared to Estimates, Evolent Health (EVH) Q3 Earnings: A Look at Key Metrics
The headline numbers for Evolent Health (EVH) give insight into how the company performed in the quarter ended September 2024, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.
Evolent Health (EVH) Q3 Earnings and Revenues Lag Estimates
Evolent Health (EVH) came out with quarterly earnings of $0.04 per share, missing the Zacks Consensus Estimate of $0.30 per share. This compares to earnings of $0.30 per share a year ago.
Unlocking Q3 Potential of Evolent Health (EVH): Exploring Wall Street Estimates for Key Metrics
Beyond analysts' top -and-bottom-line estimates for Evolent Health (EVH), evaluate projections for some of its key metrics to gain a better insight into how the business might have performed for the quarter ended September 2024.
Why Evolent Health (EVH) is Poised to Beat Earnings Estimates Again
Evolent Health (EVH) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.
Evolent Health (EVH) Reports Next Week: What to Know Ahead of the Release
Evolent Health (EVH) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Evolent Health Inc (EVH) Stock Price Down 3.2% on Oct 2
Shares of Evolent Health Inc (EVH, Financial) fell 3.20% in mid-day trading on Oct 2. The stock reached an intraday low of $25.76, before recovering slightly to $26.19, down from its previous close of $27.05.
